Supernus Pharmaceuticals Inc
SWB:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
H
|
Henry Schein Inc
XMUN:HS2
|
US |
|
M
|
Mondelez International Inc
XBER:KTF
|
US |
|
C
|
Ciena Corp
XMUN:CIE1
|
US |
|
Community Healthcare Trust Inc
F:4U9
|
US |
|
Q
|
QinetiQ Group PLC
XMUN:QY6
|
UK |
|
F
|
Farmland Partners Inc
F:0FA
|
US |
|
P
|
Pixelworks Inc
XMUN:PXLX
|
US |
|
P
|
Polytec Holding AG
XMUN:P4N
|
AT |
|
U
|
USANA Health Sciences Inc
XMUN:USJ
|
US |
|
A
|
Aegon NV
XBER:AEND
|
NL |
|
Vale SA
NYSE:VALE
|
BR |
|
Opthea Ltd
ASX:OPT
|
AU |
|
Beeks Financial Cloud Group PLC
F:1BZ
|
UK |
|
Arca Continental SAB de CV
OTC:EMBVF
|
MX |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 54.43 EUR with a low forecast of 46.93 EUR and a high forecast of 58.55 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
54.43
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 54.43 EUR with a low forecast of 46.93 EUR and a high forecast of 58.55 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
62%
The compound annual growth rate for Operating Income over the next 8 years is 62%.
